Regeneron Pharmaceuticals, Inc. (REGN)
USD 564.26
(-1.6%)
USD 564.26
(-1.6%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 4.65 Billion USD | -0.84% |
| 2022 | 5.33 Billion USD | -44.87% |
| 2021 | 9.28 Billion USD | 142.63% |
| 2020 | 3.9 Billion USD | 75.01% |
| 2019 | 2.42 Billion USD | -12.81% |
| 2018 | 2.68 Billion USD | 21.87% |
| 2017 | 2.07 Billion USD | 56.27% |
| 2016 | 1.44 Billion USD | 6.3% |
| 2015 | 1.32 Billion USD | 49.32% |
| 2014 | 876.6 Million USD | 10.32% |
| 2013 | 784.25 Million USD | 66.05% |
| 2012 | 496.66 Million USD | 323.1% |
| 2011 | -170.52 Million USD | -110.48% |
| 2010 | -75.66 Million USD | -62.84% |
| 2009 | -55.36 Million USD | 33.37% |
| 2008 | -61.32 Million USD | 27.48% |
| 2007 | -82.07 Million USD | -13.0% |
| 2006 | -93.06 Million USD | -210.83% |
| 2005 | 139.92 Million USD | 463.35% |
| 2004 | -27.22 Million USD | 70.26% |
| 2003 | -91.51 Million USD | 25.56% |
| 2002 | -113.49 Million USD | -33.96% |
| 2001 | -79.6 Million USD | -463.67% |
| 2000 | -20.85 Million USD | 23.93% |
| 1999 | -20.4 Million USD | -52.86% |
| 1998 | -9.5 Million USD | -4766.67% |
| 1997 | -9.3 Million USD | -90.32% |
| 1996 | -11.2 Million USD | -76.15% |
| 1995 | -1.7 Million USD | 152.0% |
| 1994 | -25 Million USD | 29.97% |
| 1993 | -35.7 Million USD | -119.02% |
| 1992 | -16.3 Million USD | -16.43% |
| 1991 | -8.8 Million USD | -193.33% |
| 1990 | -3 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 1.17 Billion USD | 34.12% |
| 2024 Q1 | 872.6 Million USD | -21.8% |
| 2024 Q2 | 1.21 Billion USD | 39.15% |
| 2023 Q3 | 1.11 Billion USD | -7.79% |
| 2023 Q4 | 1.26 Billion USD | 13.74% |
| 2023 FY | - USD | -0.84% |
| 2023 Q1 | 1.03 Billion USD | -24.82% |
| 2023 Q2 | 1.2 Billion USD | 16.8% |
| 2022 Q2 | 1.17 Billion USD | -0.32% |
| 2022 Q4 | 1.37 Billion USD | -15.18% |
| 2022 FY | - USD | -44.87% |
| 2022 Q1 | 1.17 Billion USD | -53.24% |
| 2022 Q3 | 1.61 Billion USD | 37.88% |
| 2021 FY | - USD | 142.63% |
| 2021 Q2 | 3.83 Billion USD | 187.51% |
| 2021 Q1 | 1.33 Billion USD | 7.71% |
| 2021 Q4 | 2.51 Billion USD | 32.22% |
| 2021 Q3 | 1.9 Billion USD | -50.39% |
| 2020 FY | - USD | 75.01% |
| 2020 Q4 | 1.23 Billion USD | 14.35% |
| 2020 Q3 | 1.08 Billion USD | 9.77% |
| 2020 Q2 | 987.4 Million USD | 35.11% |
| 2020 Q1 | 730.8 Million USD | 8.15% |
| 2019 Q4 | 675.7 Million USD | -18.51% |
| 2019 FY | - USD | -12.81% |
| 2019 Q1 | 604.8 Million USD | -15.78% |
| 2019 Q2 | 284.8 Million USD | -52.91% |
| 2019 Q3 | 829.2 Million USD | 191.15% |
| 2018 Q3 | 678.79 Million USD | 9.1% |
| 2018 Q2 | 622.18 Million USD | -0.96% |
| 2018 Q1 | 628.19 Million USD | 16.59% |
| 2018 FY | - USD | 21.87% |
| 2018 Q4 | 718.1 Million USD | 5.79% |
| 2017 Q3 | 609.5 Million USD | 7.61% |
| 2017 FY | - USD | 56.27% |
| 2017 Q4 | 538.81 Million USD | -11.6% |
| 2017 Q1 | 477.9 Million USD | 37.72% |
| 2017 Q2 | 566.37 Million USD | 18.51% |
| 2016 Q2 | 316.65 Million USD | -10.11% |
| 2016 Q3 | 390.64 Million USD | 23.36% |
| 2016 FY | - USD | 6.3% |
| 2016 Q1 | 352.28 Million USD | 52.45% |
| 2016 Q4 | 347 Million USD | -11.17% |
| 2015 Q3 | 413.09 Million USD | 14.7% |
| 2015 FY | - USD | 49.32% |
| 2015 Q2 | 360.15 Million USD | 20.22% |
| 2015 Q4 | 231.08 Million USD | -44.06% |
| 2015 Q1 | 299.58 Million USD | 21.11% |
| 2014 FY | - USD | 10.32% |
| 2014 Q3 | 196.72 Million USD | -16.44% |
| 2014 Q2 | 235.42 Million USD | 19.22% |
| 2014 Q1 | 197.46 Million USD | -6.89% |
| 2014 Q4 | 247.36 Million USD | 25.74% |
| 2013 Q2 | 167.8 Million USD | 3.29% |
| 2013 Q3 | 247.6 Million USD | 47.56% |
| 2013 FY | - USD | 66.05% |
| 2013 Q4 | 212.07 Million USD | -14.35% |
| 2013 Q1 | 162.45 Million USD | 11.52% |
| 2012 FY | - USD | 323.1% |
| 2012 Q1 | 30.61 Million USD | 181.7% |
| 2012 Q2 | 96.89 Million USD | 216.47% |
| 2012 Q3 | 211.69 Million USD | 118.48% |
| 2012 Q4 | 145.67 Million USD | -31.19% |
| 2011 Q1 | -40.98 Million USD | -220.74% |
| 2011 FY | - USD | -110.48% |
| 2011 Q4 | -37.47 Million USD | 25.32% |
| 2011 Q3 | -50.18 Million USD | 4.27% |
| 2011 Q2 | -52.41 Million USD | -27.91% |
| 2010 Q3 | -27.65 Million USD | -39.72% |
| 2010 Q4 | -12.77 Million USD | 53.8% |
| 2010 FY | - USD | -62.84% |
| 2010 Q1 | -28.65 Million USD | 16.87% |
| 2010 Q2 | -19.79 Million USD | 30.94% |
| 2009 Q1 | -18.25 Million USD | -4.94% |
| 2009 Q2 | -17.59 Million USD | 3.63% |
| 2009 Q3 | -1.29 Million USD | 92.66% |
| 2009 Q4 | -34.47 Million USD | -2570.26% |
| 2009 FY | - USD | 33.37% |
| 2008 Q3 | -20.82 Million USD | -3.85% |
| 2008 Q4 | -17.39 Million USD | 16.45% |
| 2008 FY | - USD | 27.48% |
| 2008 Q1 | -20.26 Million USD | -100.52% |
| 2008 Q2 | -20.05 Million USD | 1.07% |
| 2007 FY | - USD | -13.0% |
| 2007 Q4 | -10.1 Million USD | 75.73% |
| 2007 Q3 | -41.64 Million USD | -20.47% |
| 2007 Q2 | -34.57 Million USD | 7.9% |
| 2007 Q1 | -37.53 Million USD | -24.75% |
| 2006 Q3 | -24.54 Million USD | -19.41% |
| 2006 Q2 | -20.55 Million USD | -15.08% |
| 2006 Q1 | -17.86 Million USD | -108.11% |
| 2006 FY | - USD | -210.83% |
| 2006 Q4 | -30.09 Million USD | -22.57% |
| 2005 Q3 | -33.19 Million USD | 9.08% |
| 2005 Q1 | -51.71 Million USD | -953.62% |
| 2005 Q2 | -36.51 Million USD | 29.39% |
| 2005 FY | - USD | 463.35% |
| 2005 Q4 | 220.32 Million USD | 763.68% |
| 2004 Q3 | -7.02 Million USD | 29.45% |
| 2004 FY | - USD | 70.26% |
| 2004 Q1 | -16.3 Million USD | -19.09% |
| 2004 Q2 | -9.95 Million USD | 38.98% |
| 2004 Q4 | 6.05 Million USD | 186.3% |
| 2003 Q1 | -26.09 Million USD | 20.46% |
| 2003 FY | - USD | 25.56% |
| 2003 Q4 | -12.82 Million USD | 41.31% |
| 2003 Q3 | -22.04 Million USD | 7.98% |
| 2003 Q2 | -26.93 Million USD | 7.12% |
| 2002 Q1 | -23.18 Million USD | 14.82% |
| 2002 FY | - USD | -33.96% |
| 2002 Q2 | -27.72 Million USD | -16.65% |
| 2002 Q3 | -30 Million USD | -6.96% |
| 2002 Q4 | -32.58 Million USD | -5.98% |
| 2001 Q2 | -16.66 Million USD | -61.87% |
| 2001 FY | - USD | -463.67% |
| 2001 Q4 | -27.78 Million USD | -22.18% |
| 2001 Q3 | -21.77 Million USD | -24.93% |
| 2001 Q1 | -13.38 Million USD | -999.02% |
| 2000 FY | - USD | 23.93% |
| 2000 Q1 | -7.55 Million USD | -1354.29% |
| 2000 Q2 | -2.83 Million USD | 53.75% |
| 2000 Q3 | -14.33 Million USD | -19.65% |
| 2000 Q4 | -8.21 Million USD | 76.91% |
| 1999 Q3 | -4.2 Million USD | 46.34% |
| 1999 Q4 | 200 Thousand USD | 115.91% |
| 1999 FY | - USD | -52.86% |
| 1999 Q1 | -9.7 Million USD | -46.77% |
| 1999 Q2 | -7.5 Million USD | 9.89% |
| 1998 Q3 | -1.7 Million USD | -200.0% |
| 1998 Q4 | -5.5 Million USD | -121.43% |
| 1998 FY | - USD | -4766.67% |
| 1998 Q1 | -4 Million USD | -275.86% |
| 1998 Q2 | 1.5 Million USD | 154.9% |
| 1997 Q2 | -2.5 Million USD | -66.67% |
| 1997 FY | - USD | -90.32% |
| 1997 Q4 | 2.3 Million USD | 383.33% |
| 1997 Q3 | -100 Thousand USD | 130.0% |
| 1997 Q1 | -2.9 Million USD | -271.43% |
| 1996 FY | - USD | -76.15% |
| 1996 Q4 | -2.9 Million USD | -50.0% |
| 1996 Q3 | -2.9 Million USD | 0.0% |
| 1996 Q2 | -2.2 Million USD | 450.0% |
| 1996 Q1 | -3.2 Million USD | -111.43% |
| 1995 Q3 | -800 Thousand USD | 23.33% |
| 1995 Q4 | -1.4 Million USD | -5.41% |
| 1995 Q2 | 200 Thousand USD | 150.0% |
| 1995 Q1 | -500 Thousand USD | 130.77% |
| 1995 FY | - USD | 152.0% |
| 1994 Q4 | -3.9 Million USD | -50.0% |
| 1994 FY | - USD | 29.97% |
| 1994 Q1 | -9.5 Million USD | 7.77% |
| 1994 Q2 | -9 Million USD | 5.26% |
| 1994 Q3 | -2.6 Million USD | 71.11% |
| 1993 Q3 | -8.5 Million USD | 13.27% |
| 1993 Q2 | -9.1 Million USD | -15.29% |
| 1993 FY | - USD | -119.02% |
| 1993 Q1 | -8.5 Million USD | -54.55% |
| 1993 Q4 | -10.3 Million USD | -21.18% |
| 1992 Q1 | -2.8 Million USD | 44.0% |
| 1992 Q2 | -3 Million USD | -7.14% |
| 1992 Q3 | -5.1 Million USD | -70.0% |
| 1992 Q4 | -5.5 Million USD | -7.84% |
| 1992 FY | - USD | -16.43% |
| 1991 FY | - USD | -366.67% |
| 1991 Q4 | -3.4 Million USD | -21.95% |
| 1991 Q1 | 2 Million USD | 128.57% |
| 1991 Q3 | -2.3 Million USD | -24.24% |
| 1991 Q2 | -1.8 Million USD | -265.0% |
| 1990 Q3 | 1.3 Million USD | 8.33% |
| 1990 Q2 | 1.2 Million USD | 0.0% |
| 1990 Q1 | 1.2 Million USD | 0.0% |
| 1990 Q4 | -7 Million USD | -638.46% |
| 1990 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AbCellera Biologics Inc. | -192.15 Million USD | 2522.069% |
| Alkermes plc | 495.04 Million USD | -840.149% |
| Agenus Inc. | -145.92 Million USD | 3289.468% |
| Aptorum Group Limited | -9.59 Million USD | 48586.316% |
| Ardelyx, Inc. | -55.35 Million USD | 8508.064% |
| Dyadic International, Inc. | -8.22 Million USD | 56653.434% |
| Eton Pharmaceuticals, Inc. | -291 Thousand USD | 1599481.443% |
| Lantern Pharma Inc. | -15.78 Million USD | 29581.8% |
| Inhibikase Therapeutics, Inc. | -19.91 Million USD | 23473.382% |
| Novavax, Inc. | -487.39 Million USD | 1054.923% |
| Janux Therapeutics, Inc. | -71.02 Million USD | 6652.996% |
| Pyxis Oncology, Inc. | -78.49 Million USD | 6029.446% |
| TransCode Therapeutics, Inc. | -17.97 Million USD | 25994.862% |
| Ocuphire Pharma, Inc. | -9.96 Million USD | 46791.413% |
| Outlook Therapeutics, Inc. | -57.37 Million USD | 8211.764% |
| Madrigal Pharmaceuticals, Inc. | -379.96 Million USD | 1324.889% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | 19402.503% |
| SELLAS Life Sciences Group, Inc. | 529 Thousand USD | -879710.964% |
| Syros Pharmaceuticals, Inc. | -157.19 Million USD | 3060.781% |
| Barinthus Biotherapeutics plc | -74.81 Million USD | 6320.956% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 23187.455% |
| Xeris Biopharma Holdings, Inc. | -23.73 Million USD | 19709.016% |
| Clearside Biomedical, Inc. | -23.05 Million USD | 20284.751% |
| C4 Therapeutics, Inc. | -122.1 Million USD | 3911.7% |
| Alnylam Pharmaceuticals, Inc. | -258.24 Million USD | 1902.263% |
| AlloVir, Inc. | -190.14 Million USD | 2547.698% |
| Arrowhead Pharmaceuticals, Inc. | -175.67 Million USD | 2749.369% |
| VYNE Therapeutics Inc. | -29.25 Million USD | 16007.444% |
| Bicycle Therapeutics plc | -183.4 Million USD | 2637.732% |
| BioXcel Therapeutics, Inc. | -165.42 Million USD | 2913.548% |
| ChromaDex Corporation | -3.89 Million USD | 119622.342% |
| Chimerix, Inc. | -92.97 Million USD | 5105.916% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 10573.775% |
| Caribou Biosciences, Inc. | -112.53 Million USD | 4235.817% |
| CRISPR Therapeutics AG | -202.7 Million USD | 2396.091% |
| Precision BioSciences, Inc. | -32.04 Million USD | 14625.311% |
| Fate Therapeutics, Inc. | -172.22 Million USD | 2802.332% |
| Fortress Biotech, Inc. | -133.64 Million USD | 3582.562% |
| Fortress Biotech, Inc. | -133.64 Million USD | 3582.562% |
| HOOKIPA Pharma Inc. | -77.34 Million USD | 6117.61% |
| ImmuCell Corporation | -2.5 Million USD | 185964.892% |
| IDEAYA Biosciences, Inc. | -130.42 Million USD | 3668.597% |
| Immix Biopharma, Inc. | -16.13 Million USD | 28944.214% |
| Incyte Corporation | 919.42 Million USD | -406.207% |
| Innoviva, Inc. | 248.96 Million USD | -1769.457% |
| IO Biotech, Inc. | -91.22 Million USD | 5201.723% |
| Jaguar Health, Inc. | -33.13 Million USD | 14147.871% |
| Keros Therapeutics, Inc. | -152.17 Million USD | 3158.412% |
| Ligand Pharmaceuticals Incorporated | 101.72 Million USD | -4475.187% |
| ContextLogic Inc. | -324 Million USD | 1536.481% |
| MiMedx Group, Inc. | 40.51 Million USD | -11387.03% |
| MEI Pharma, Inc. | 26.38 Million USD | -17542.911% |
| NextCure, Inc. | -59.03 Million USD | 7983.264% |
| Onconetix, Inc. | -36.7 Million USD | 12779.42% |
| Oncternal Therapeutics, Inc. | 2.23 Million USD | -208141.611% |
| Opthea Limited | -200.01 Million USD | 2426.882% |
| Psyence Biomedical Ltd. | -2.75 Million USD | 169246.454% |
| Vaxcyte, Inc. | -464.88 Million USD | 1101.151% |
| PDS Biotechnology Corporation | -40.08 Million USD | 11710.836% |
| Precigen, Inc. | -89.22 Million USD | 5316.193% |
| Pharming Group N.V. | 9.87 Million USD | -47021.596% |
| Phathom Pharmaceuticals, Inc. | -159.04 Million USD | 3026.268% |
| Pieris Pharmaceuticals, Inc. | -22.76 Million USD | 20547.237% |
| PureTech Health plc | -11.62 Million USD | 40129.242% |
| Rigel Pharmaceuticals, Inc. | -16.98 Million USD | 27508.28% |
| Avidity Biosciences, Inc. | -233.49 Million USD | 2093.259% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | 19402.503% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 5423.527% |
| Sol-Gel Technologies Ltd. | -28.96 Million USD | 16169.468% |
| Acelyrin, Inc. | -381.52 Million USD | 1319.891% |
| Salarius Pharmaceuticals, Inc. | -12.88 Thousand USD | 36121479.383% |
| Summit Therapeutics Inc. | 1 Million USD | -464855.045% |
| Sensei Biotherapeutics, Inc. | -33.38 Million USD | 14040.574% |
| Senti Biosciences, Inc. | -61.33 Million USD | 7688.04% |
| Stoke Therapeutics, Inc. | -112.3 Million USD | 4244.287% |
| Elevation Oncology, Inc. | -41.46 Million USD | 11323.865% |
| Alaunos Therapeutics, Inc. | -30.9 Million USD | 15160.186% |
| Telomir Pharmaceuticals, Inc. Common Stock | -6.11 Million USD | 76191.964% |
| Entrada Therapeutics, Inc. | -321 Thousand USD | 1450006.542% |
| VistaGen Therapeutics, Inc. | -32.45 Million USD | 14441.355% |
| Kintara Therapeutics, Inc. | -8.39 Million USD | 55533.54% |
| Wave Life Sciences Ltd. | -58.79 Million USD | 8016.652% |
| Seer, Inc. | -97.88 Million USD | 4854.763% |
| Verrica Pharmaceuticals Inc. | -62.19 Million USD | 7582.998% |
| Aadi Bioscience, Inc. | -65.36 Million USD | 7220.324% |
| ESSA Pharma Inc. | -26.45 Million USD | 17692.688% |
| GlycoMimetics, Inc. | -39.12 Million USD | 11996.633% |
| GT Biopharma, Inc. | 5.97 Million USD | -77742.449% |
| Inhibrx Biosciences, Inc. | -206.69 Million USD | 2351.745% |
| Akebia Therapeutics, Inc. | -6.86 Million USD | 67866.453% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | -5261.24% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 8300.655% |
| Orchestra BioMed Holdings, Inc. | -51.21 Million USD | 9186.862% |
| Alzamend Neuro, Inc. | -9.88 Million USD | 47174.388% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 962.004% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | 67708.948% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | 10031.714% |
| Rocket Pharmaceuticals, Inc. | -236.62 Million USD | 2066.935% |
| Aptose Biosciences Inc. | -52.26 Million USD | 9004.492% |
| ZyVersa Therapeutics, Inc. | -107.74 Million USD | 4419.709% |
| Soligenix, Inc. | -7.85 Million USD | 59367.654% |
| Century Therapeutics, Inc. | -121.2 Million USD | 3939.846% |
| Kura Oncology, Inc. | -164.95 Million USD | 2921.497% |
| TScan Therapeutics, Inc. | -80.09 Million USD | 5910.632% |
| Intensity Therapeutics, Inc. | -10.08 Million USD | 46245.152% |
| Ocean Biomedical, Inc. | -957.73 Thousand USD | 486057.03% |
| CytomX Therapeutics, Inc. | -4.3 Million USD | 108111.139% |
| Autolus Therapeutics plc | -156.77 Million USD | 3068.808% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 5597.714% |
| EyePoint Pharmaceuticals, Inc. | -69 Million USD | 6845.12% |
| Eterna Therapeutics Inc. | -19.93 Million USD | 23448.049% |
| Adaptive Biotechnologies Corporation | -189.27 Million USD | 2558.988% |
| GRI Bio, Inc. | -10.89 Million USD | 42806.919% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | 103166.735% |
| Tenaya Therapeutics, Inc. | -122.5 Million USD | 3899.161% |
| IGM Biosciences, Inc. | -253.35 Million USD | 1937.005% |
| INmune Bio, Inc. | - USD | -Infinity% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 4584.161% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | 12305.107% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | 30458.282% |
| Entero Therapeutics, Inc. | -15.74 Million USD | 29663.161% |
| Milestone Pharmaceuticals Inc. | -56.84 Million USD | 8287.527% |
| X4 Pharmaceuticals, Inc. | -107.1 Million USD | 4445.537% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 1849.719% |
| Coherus BioSciences, Inc. | -193.93 Million USD | 2499.827% |
| Verastem, Inc. | -83.16 Million USD | 5696.277% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 9303.116% |
| Pliant Therapeutics, Inc. | -158.22 Million USD | 3041.452% |
| Tonix Pharmaceuticals Holding Corp. | -114.08 Million USD | 4179.447% |
| Histogen Inc. | -10.5 Million USD | 44413.053% |
| Aprea Therapeutics, Inc. | -14.27 Million USD | 32693.103% |
| Surrozen, Inc. | -41.13 Million USD | 11415.553% |
| Organovo Holdings, Inc. | -14.8 Million USD | 31534.554% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | -145126186.249% |
| Ovid Therapeutics Inc. | -58.71 Million USD | 8027.01% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 9173.576% |
| CASI Pharmaceuticals, Inc. | -21.53 Million USD | 21708.246% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.33 Million USD | 55919.108% |
| Centessa Pharmaceuticals plc | -166.06 Million USD | 2902.617% |
| Hepion Pharmaceuticals, Inc. | -49.25 Million USD | 9548.528% |
| Arcturus Therapeutics Holdings Inc. | -24.16 Million USD | 19359.29% |
| BioRestorative Therapies, Inc. | -15.05 Million USD | 31014.566% |
| Apollomics, Inc. | -171.74 Million USD | 2809.916% |
| Amarin Corporation plc | -50.9 Million USD | 9243.536% |
| Mesoblast Limited | -61.33 Million USD | 7688.658% |
| Turnstone Biologics Corp. | -56.23 Million USD | 8376.488% |
| Kymera Therapeutics, Inc. | -143.2 Million USD | 3350.117% |
| Synaptogenix, Inc. | -8.3 Million USD | 56124.027% |
| Tiziana Life Sciences Ltd | -15.33 Million USD | 30442.265% |
| Aurinia Pharmaceuticals Inc. | -63.04 Million USD | 7482.112% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 97235.198% |
| Monopar Therapeutics Inc. | 429.03 Thousand USD | -1084696.487% |
| Exelixis, Inc. | 196.6 Million USD | -2267.321% |
| Better Therapeutics, Inc. | -38.26 Million USD | 12264.027% |
| Nurix Therapeutics, Inc. | -141.4 Million USD | 3391.304% |
| Apellis Pharmaceuticals, Inc. | -495.21 Million USD | 1039.842% |
| NLS Pharmaceutics AG | -11.79 Million USD | 39556.902% |
| Dermata Therapeutics, Inc. | 247.21 Thousand USD | -1882545.136% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | 15873.741% |
| Gritstone bio, Inc. | -126.86 Million USD | 3768.682% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 7261.96% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | 116456.571% |
| Avid Bioservices, Inc. | -11.48 Million USD | 40638.281% |
| Insmed Incorporated | -654.73 Million USD | 810.848% |
| Virpax Pharmaceuticals, Inc. | -2.24 Million USD | 206979.17% |
| MediWound Ltd. | -4.89 Million USD | 95219.559% |
| OmniAb, Inc. | -49.73 Million USD | 9458.75% |
| Alector, Inc. | -142.89 Million USD | 3357.145% |
| Seres Therapeutics, Inc. | -85.43 Million USD | 5547.714% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 9024.983% |
| Zai Lab Limited | -366.57 Million USD | 1369.652% |
| Revance Therapeutics, Inc. | -290.63 Million USD | 1701.379% |
| Aura Biosciences, Inc. | -83.69 Million USD | 5660.839% |
| Lyell Immunopharma, Inc. | -225.24 Million USD | 2166.247% |
| Immunic, Inc. | -99.11 Million USD | 4795.9% |
| Tarsus Pharmaceuticals, Inc. | -131.67 Million USD | 3634.746% |
| Veracyte, Inc. | -49.4 Million USD | 9519.741% |
| InMed Pharmaceuticals Inc. | -7.06 Million USD | 65986.827% |
| FibroGen, Inc. | -261.4 Million USD | 1880.456% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | 41875.424% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | 66575.96% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.71 Million USD | 24966.341% |
| Jazz Pharmaceuticals plc | 1.44 Billion USD | -221.107% |
| Cyclacel Pharmaceuticals, Inc. | -25.42 Million USD | 18407.765% |
| Amylyx Pharmaceuticals, Inc. | 39.89 Million USD | -11567.586% |
| TG Therapeutics, Inc. | 26.1 Million USD | -17732.184% |
| Galecto, Inc. | -37.51 Million USD | 12504.915% |
| Calithera Biosciences, Inc. | -38.26 Million USD | 12263.073% |
| Fortrea Holdings Inc. | 167.3 Million USD | -2681.949% |
| KalVista Pharmaceuticals, Inc. | -134.28 Million USD | 3566.041% |
| Aptevo Therapeutics Inc. | -28.31 Million USD | 16539.546% |
| XBiotech Inc. | -35.76 Million USD | 13112.917% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 7261.96% |
| Lyra Therapeutics, Inc. | -65.25 Million USD | 7232.874% |
| Foghorn Therapeutics Inc. | -104.45 Million USD | 4555.699% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | 18229.48% |
| Theravance Biopharma, Inc. | -40.86 Million USD | 11488.651% |
| Ultragenyx Pharmaceutical Inc. | -516.45 Million USD | 1001.184% |
| Metagenomi, Inc. Common Stock | -56.02 Million USD | 8407.956% |
| Vaxxinity, Inc. | -56.05 Thousand USD | 8303609.304% |
| BioCryst Pharmaceuticals, Inc. | -116.33 Million USD | 4100.688% |
| Gain Therapeutics, Inc. | -22.16 Million USD | 21093.656% |
| Cartesian Therapeutics, Inc. | -235.06 Million USD | 2079.971% |
| NexImmune, Inc. | -28.16 Million USD | 16623.292% |
| Creative Medical Technology Holdings, Inc. | -5.52 Million USD | 84330.56% |
| Marker Therapeutics, Inc. | -11.79 Million USD | 39568.221% |
| Chemomab Therapeutics Ltd. | -25.39 Million USD | 18429.395% |
| Scopus BioPharma Inc. | -11.71 Million USD | 39834.831% |
| RAPT Therapeutics, Inc. | -125.84 Million USD | 3798.33% |
| Ainos, Inc. | -8.77 Million USD | 53150.815% |
| Pluri Inc. | -20.22 Million USD | 23112.114% |
| Prothena Corporation plc | -190.1 Million USD | 2548.187% |
| Adaptimmune Therapeutics plc | -128.19 Million USD | 3730.478% |
| Celularity Inc. | -183.94 Million USD | 2630.199% |
| Rallybio Corporation | -72.37 Million USD | 6530.851% |
| Cue Biopharma, Inc. | -46.05 Million USD | 10206.401% |
| MeiraGTx Holdings plc | -57.05 Million USD | 8257.821% |
| Omeros Corporation | -163.61 Million USD | 2944.692% |
| Humacyte, Inc. | -96.45 Million USD | 4925.105% |
| Immunocore Holdings plc | -59.64 Million USD | 7902.645% |
| Cocrystal Pharma, Inc. | -19.37 Million USD | 24125.397% |
| Cidara Therapeutics, Inc. | -24.36 Million USD | 19201.991% |
| Blueprint Medicines Corporation | -474.61 Million USD | 1080.633% |
| CalciMedica, Inc. | -34.18 Million USD | 13713.15% |
| Cabaletta Bio, Inc. | -73.23 Million USD | 6455.245% |
| Marinus Pharmaceuticals, Inc. | -125.49 Million USD | 3808.615% |
| Scholar Rock Holding Corporation | -168.45 Million USD | 2862.94% |
| Sana Biotechnology, Inc. | -252.39 Million USD | 1944.051% |
| Pulmatrix, Inc. | -12.64 Million USD | 36903.732% |
| Elicio Therapeutics, Inc. | -32.96 Million USD | 14218.182% |
| Vigil Neuroscience, Inc. | -88.46 Million USD | 5360.945% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 1019.23% |
| Adlai Nortye Ltd. American Depositary Shares | -101.21 Million USD | 4698.33% |
| Cytokinetics, Incorporated | -456.68 Million USD | 1119.129% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | 14046.004% |
| Nutriband Inc. | -5.12 Million USD | 90970.805% |
| Protara Therapeutics, Inc. | -43.27 Million USD | 10855.685% |
| Vor Biopharma Inc. | -114.37 Million USD | 4169.388% |
| Roivant Sciences Ltd. | -996.51 Million USD | 567.048% |
| Evogene Ltd. | -23.2 Million USD | 20157.749% |
| ProKidney Corp. | -147.66 Million USD | 3251.779% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 7311.901% |
| Hoth Therapeutics, Inc. | -153.14 Thousand USD | 3039101.234% |
| BridgeBio Pharma, Inc. | -565.46 Million USD | 923.07% |
| CorMedix Inc. | -48.88 Million USD | 9620.316% |
| BioLineRx Ltd. | -57.06 Million USD | 8256.534% |
| Tango Therapeutics, Inc. | -111.75 Million USD | 4264.534% |
| Galectin Therapeutics Inc. | -202 Thousand USD | 2304159.406% |
| Atai Life Sciences N.V. | -36.31 Million USD | 12917.603% |
| Renovaro Biosciences Inc. | -79.51 Million USD | 5953.089% |
| Aerovate Therapeutics, Inc. | -81.31 Million USD | 5823.808% |
| Zentalis Pharmaceuticals, Inc. | -275.5 Million USD | 1789.346% |
| Sagimet Biosciences Inc. | -30.74 Million USD | 15240.534% |
| MediciNova, Inc. | -9.87 Million USD | 47207.43% |
| Praxis Precision Medicines, Inc. | -125.94 Million USD | 3795.54% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | 304256.121% |
| GeoVax Labs, Inc. | -26.66 Million USD | 17551.873% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 2168.616% |
| Biomea Fusion, Inc. | -124.62 Million USD | 3834.714% |
| PTC Therapeutics, Inc. | -330.34 Million USD | 1508.912% |
| Mereo BioPharma Group plc | -26.05 Million USD | 17962.297% |
| Cullinan Oncology, Inc. | -190.33 Million USD | 2545.216% |
| Syndax Pharmaceuticals, Inc. | -229.94 Million USD | 2124.076% |
| Absci Corporation | -95.45 Million USD | 4975.703% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | 15601.082% |
| 4D Molecular Therapeutics, Inc. | -107.11 Million USD | 4444.928% |
| Dyne Therapeutics, Inc. | -233.47 Million USD | 2093.438% |
| Kiniksa Pharmaceuticals, Ltd. | -22.85 Million USD | 20464.034% |
| Ventyx Biosciences, Inc. | -207.83 Million USD | 2339.362% |
| Allakos Inc. | -189.91 Million USD | 2550.675% |
| Imunon, Inc. | -19.87 Million USD | 23513.496% |
| Fulcrum Therapeutics, Inc. | -108.49 Million USD | 4389.902% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | -4196.555% |
| BioAtla, Inc. | -122.24 Million USD | 3907.397% |
| NLS Pharmaceutics AG | -11.79 Million USD | 39556.902% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | 29629.852% |
| Allogene Therapeutics, Inc. | -300.29 Million USD | 1649.886% |
| Larimar Therapeutics, Inc. | -41.44 Million USD | 11329.281% |
| XOMA Corporation | -39.36 Million USD | 11924.094% |
| Kezar Life Sciences, Inc. | -99.25 Million USD | 4789.181% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 4055.971% |
| aTyr Pharma, Inc. | -52.17 Million USD | 9019.851% |
| Aligos Therapeutics, Inc. | -83.81 Million USD | 5652.944% |
| Akero Therapeutics, Inc. | -148.63 Million USD | 3231.379% |
| Viridian Therapeutics, Inc. | -234.56 Million USD | 2084.183% |
| Eliem Therapeutics, Inc. | -13.65 Million USD | 34189.211% |
| EyeGate Pharmaceuticals, Inc. | -8.04 Million USD | 57971.504% |
| Akari Therapeutics, Plc | -16.8 Million USD | 27800.274% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | -2466276.268% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | -929.811% |
| Lexaria Bioscience Corp. | -6.38 Million USD | 72951.357% |
| UroGen Pharma Ltd. | -63.83 Million USD | 7391.441% |
| Sutro Biopharma, Inc. | -67.91 Million USD | 6952.978% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | 64180.852% |
| Orgenesis Inc. | -60.71 Million USD | 7765.272% |
| Entera Bio Ltd. | -8.8 Million USD | 52964.607% |
| GH Research PLC | -41.15 Million USD | 11409.504% |
| Lisata Therapeutics, Inc. | -25.51 Million USD | 18338.175% |
| Reneo Pharmaceuticals, Inc. | -82.23 Million USD | 5759.772% |
| Xencor, Inc. | -125.87 Million USD | 3797.507% |
| 60 Degrees Pharmaceuticals, Inc. | -1.42 Million USD | 326356.795% |
| Replimune Group, Inc. | -230.19 Million USD | 2121.825% |
| Coeptis Therapeutics Holdings, Inc. | -20.15 Million USD | 23189.038% |
| Vanda Pharmaceuticals Inc. | -10.94 Million USD | 42635.186% |
| Lexaria Bioscience Corp. | -6.38 Million USD | 72951.357% |
| Portage Biotech Inc. | -18.19 Million USD | 25673.933% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | 304256.121% |
| Olema Pharmaceuticals, Inc. | -104.58 Million USD | 4550.203% |
| OncoCyte Corporation | -23.12 Million USD | 20228.011% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | 41286.291% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | 40723.771% |
| Purple Biotech Ltd. | -22.22 Million USD | 21041.282% |
| CollPlant Biotechnologies Ltd. | -6.41 Million USD | 72708.424% |
| scPharmaceuticals Inc. | -46.06 Million USD | 10204.427% |
| ProMIS Neurosciences, Inc. | -17.8 Million USD | 26232.976% |
| HilleVax, Inc. | -132.46 Million USD | 3613.505% |
| NeuroSense Therapeutics Ltd. | -10.63 Million USD | 43871.278% |
| Tharimmune, Inc. | -9.3 Million USD | 50131.233% |
| Genprex, Inc. | -31.06 Million USD | 15084.273% |
| Neumora Therapeutics, Inc. Common Stock | -187.52 Million USD | 2581.896% |
| Atossa Therapeutics, Inc. | -31.35 Million USD | 14944.039% |
| XTL Biopharmaceuticals Ltd. | -764 Thousand USD | 609288.482% |
| Virios Therapeutics, Inc. | 150.9 Thousand USD | -3084112.479% |
| OKYO Pharma Limited | -15.74 Thousand USD | 29558327.014% |
| Savara Inc. | -59.13 Million USD | 7970.732% |
| Curis, Inc. | -45.13 Million USD | 10410.818% |
| Daré Bioscience, Inc. | -30.7 Million USD | 15259.511% |
| Carmell Therapeutics Corporation | -15.19 Million USD | 30737.579% |
| Titan Pharmaceuticals, Inc. | -7.16 Million USD | 65057.432% |
| Achieve Life Sciences, Inc. | -26.73 Million USD | 17509.292% |
| BeiGene, Ltd. | -1.12 Billion USD | 513.85% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | 28651.272% |
| Revolution Medicines, Inc. Warrant | -430.58 Million USD | 1180.909% |
| Protagonist Therapeutics, Inc. | -90.34 Million USD | 5251.871% |
| Erasca, Inc. | -121.31 Million USD | 3936.617% |
| bluebird bio, Inc. | -167.16 Million USD | 2884.262% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | 103555.266% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | -1399.981% |
| DBV Technologies S.A. | -85.98 Million USD | 5512.993% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | 103555.266% |
| Moderna, Inc. | -3.28 Billion USD | 241.767% |
| Vincerx Pharma, Inc. | -42.6 Million USD | 11023.044% |
| Fresh Tracks Therapeutics, Inc. | -5.64 Million USD | 82504.391% |
| Molecular Templates, Inc. | 1.43 Million USD | -325368.531% |
| Acrivon Therapeutics, Inc. Common Stock | -59.85 Million USD | 7876.181% |
| Travere Therapeutics, Inc. | -326.24 Million USD | 1526.592% |
| Monte Rosa Therapeutics, Inc. | -137.08 Million USD | 3495.021% |
| Spruce Biosciences, Inc. | -47.36 Million USD | 9926.036% |
| Celldex Therapeutics, Inc. | -139.03 Million USD | 3447.527% |
| Cogent Biosciences, Inc. | -205.86 Million USD | 2360.857% |
| MacroGenics, Inc. | 2.01 Million USD | -230648.637% |
| RenovoRx, Inc. | -11.39 Million USD | 40962.16% |
| Adicet Bio, Inc. | -136.53 Million USD | 3508.796% |
| Prime Medicine, Inc. | -193.75 Million USD | 2502.056% |
| Aditxt, Inc. | -25.45 Million USD | 18381.902% |
| Adagene Inc. | -14.95 Million USD | 31230.138% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 63768.093% |
| Quantum-Si incorporated | -91.8 Million USD | 5169.714% |
| Maravai LifeSciences Holdings, Inc. | 712.4 Million USD | -553.304% |
| Acurx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Voyager Therapeutics, Inc. | 126.45 Million USD | -3580.519% |
| SciSparc Ltd. | -5.28 Million USD | 88214.351% |
| Vericel Corporation | 2.86 Million USD | -162406.983% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | 4888554.752% |
| Minerva Neurosciences, Inc. | -21.69 Million USD | 21556.401% |
| Generation Bio Co. | -133.3 Million USD | 3591.523% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 5705.444% |
| Black Diamond Therapeutics, Inc. | -86.02 Million USD | 5510.413% |
| Arcutis Biotherapeutics, Inc. | -227.43 Million USD | 2146.396% |
| Invivyd, Inc. | -196.61 Million USD | 2467.164% |
| Relay Therapeutics, Inc. | -374.15 Million USD | 1343.93% |
| Quoin Pharmaceuticals, Ltd. | -9.27 Million USD | 50281.147% |
| Spero Therapeutics, Inc. | 27.15 Million USD | -17040.016% |
| Artelo Biosciences, Inc. | -10.28 Million USD | 45352.309% |
| 2seventy bio, Inc. | -206.41 Million USD | 2354.745% |
| ADMA Biologics, Inc. | 5.12 Million USD | -90802.344% |
| Clene Inc. | -43.24 Million USD | 10863.396% |
| Capricor Therapeutics, Inc. | -23 Million USD | 20327.757% |
| Boundless Bio, Inc. Common Stock | -48.47 Million USD | 9700.842% |
| GeoVax Labs, Inc. | -26.66 Million USD | 17551.873% |
| Recursion Pharmaceuticals, Inc. | -299.56 Million USD | 1653.648% |
| Citius Pharmaceuticals, Inc. | -36.72 Million USD | 12771.61% |
| Contineum Therapeutics, Inc. Class A Common Stock | 23.57 Million USD | -19643.775% |
| Relmada Therapeutics, Inc. | 4.91 Million USD | -94685.301% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | 14428.551% |
| ALX Oncology Holdings Inc. | -158.4 Million USD | 3038.183% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 780.135% |
| Evaxion Biotech A/S | -21.4 Million USD | 21845.55% |
| Ocular Therapeutix, Inc. | -66.41 Million USD | 7107.754% |
| Verve Therapeutics, Inc. | -217.66 Million USD | 2238.201% |
| Trevena, Inc. | -35.28 Million USD | 13289.186% |
| Surrozen, Inc. | -41.13 Million USD | 11415.553% |
| Tyra Biosciences, Inc. | -79.59 Million USD | 5947.573% |
| Cingulate Inc. | -22.95 Million USD | 20377.944% |
| Galmed Pharmaceuticals Ltd. | -7.46 Million USD | 62480.378% |
| Unity Biotechnology, Inc. | -37.28 Million USD | 12583.437% |
| Tenax Therapeutics, Inc. | -8.22 Million USD | 56676.588% |
| Terns Pharmaceuticals, Inc. | -102.26 Million USD | 4651.073% |
| ACADIA Pharmaceuticals Inc. | -67.82 Million USD | 6961.869% |
| Connect Biopharma Holdings Limited | -58.37 Million USD | 8073.343% |
| Clearmind Medicine Inc. | -8.71 Million USD | 53531.068% |
| Kronos Bio, Inc. | -121.83 Million USD | 3920.241% |
| Bolt Biotherapeutics, Inc. | -74.34 Million USD | 6360.526% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | 190735.427% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 4716.025% |
| Statera Biopharma, Inc. | 38.93 Million USD | -11853.784% |
| ImmunityBio, Inc. | -436.18 Million USD | 1167.032% |
| Korro Bio, Inc. | -80.9 Million USD | 5852.744% |
| Kineta, Inc. | -15.71 Million USD | 29718.175% |
| BioVie Inc. | -31.95 Million USD | 14667.041% |
| Codexis, Inc. | -49.28 Million USD | 9543.824% |
| Celularity Inc. | -183.94 Million USD | 2630.199% |
| Crinetics Pharmaceuticals, Inc. | -221.51 Million USD | 2201.124% |
| Celcuity Inc. | -58.3 Million USD | 8081.827% |
| Virax Biolabs Group Limited | -6.6 Million USD | 70520.617% |
| Cibus, Inc. | -314.58 Million USD | 1579.473% |
| Eledon Pharmaceuticals, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | 13897.172% |
| IN8bio, Inc. | -28.5 Million USD | 16428.235% |
| Kodiak Sciences Inc. | -259.02 Million USD | 1896.829% |
| Annexon, Inc. | -141.57 Million USD | 3387.445% |
| Adverum Biotechnologies, Inc. | -112.59 Million USD | 4233.429% |
| Assembly Biosciences, Inc. | -64.19 Million USD | 7349.984% |
| Avalo Therapeutics, Inc. | -27.95 Million USD | 16748.9% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 2123.477% |
| Eyenovia, Inc. | -24.1 Million USD | 19407.198% |
| Puma Biotechnology, Inc. | 44.78 Million USD | -10292.551% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | 1436581.481% |
| Xilio Therapeutics, Inc. | -73.8 Million USD | 6406.162% |
| Arcellx, Inc. | -64.14 Million USD | 7355.749% |
| Cardiff Oncology, Inc. | -45.01 Million USD | 10439.45% |
| Enanta Pharmaceuticals, Inc. | -123.47 Million USD | 3869.315% |
| Regulus Therapeutics Inc. | -30.88 Million USD | 15170.915% |
| Moolec Science SA | -52.07 Million USD | 9037.402% |
| Acumen Pharmaceuticals, Inc. | -51.6 Million USD | 9118.719% |
| Geron Corporation | -174.78 Million USD | 2762.86% |
| LAVA Therapeutics N.V. | -40.41 Million USD | 11615.451% |
| Royalty Pharma plc | 1.88 Billion USD | -146.61% |
| Atea Pharmaceuticals, Inc. | -119.59 Million USD | 3991.699% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | 50014.985% |
| TFF Pharmaceuticals, Inc. | -20.74 Million USD | 22539.877% |
| Mersana Therapeutics, Inc. | -166.08 Million USD | 2902.384% |
| Humacyte, Inc. | -96.45 Million USD | 4925.105% |
| Structure Therapeutics Inc. | -102.45 Million USD | 4642.5% |
| 89bio, Inc. | -134.46 Million USD | 3561.324% |
| PMV Pharmaceuticals, Inc. | -78.87 Million USD | 6000.729% |
| Avenue Therapeutics, Inc. | 4.05 Million USD | -114761.797% |
| Genelux Corporation | -24.16 Million USD | 19360.087% |
| Trevi Therapeutics, Inc. | -33.8 Million USD | 13869.822% |
| Lexicon Pharmaceuticals, Inc. | -163.46 Million USD | 2947.232% |
| Notable Labs, Ltd. | -14.4 Million USD | 32420.833% |
| Liquidia Corporation | -70.05 Million USD | 6744.017% |
| Mustang Bio, Inc. | -48.06 Million USD | 9783.54% |
| Immunovant, Inc. | -269.97 Million USD | 1823.918% |
| Quantum-Si incorporated | -91.8 Million USD | 5169.714% |
| Arbutus Biopharma Corporation | -70.98 Million USD | 6656.504% |
| DiaMedica Therapeutics Inc. | -19.3 Million USD | 24205.034% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 4662.404% |
| Acasti Pharma Inc. | -11.3 Million USD | 41283.966% |
| MiNK Therapeutics, Inc. | -22.25 Million USD | 21014.705% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | 30458.282% |
| Xenon Pharmaceuticals Inc. | -210.51 Million USD | 2310.885% |
| Elevai Labs, Inc. Common Stock | -4.27 Million USD | 109088.903% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | 29408.564% |
| Tempest Therapeutics, Inc. | -28.77 Million USD | 16273.895% |
| Soleno Therapeutics, Inc. | -37.03 Million USD | 12668.728% |
| PepGen Inc. | -83.58 Million USD | 5668.424% |
| Moleculin Biotech, Inc. | -29.5 Million USD | 15874.81% |
| United Therapeutics Corporation | 1.38 Billion USD | -235.607% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 20426.68% |
| Solid Biosciences Inc. | -93.43 Million USD | 5081.27% |
| BriaCell Therapeutics Corp. | -4.77 Million USD | 97636.829% |
| Immuneering Corporation | -58.06 Million USD | 8116.079% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | -145126186.249% |
| Silo Pharma, Inc. | -3.62 Million USD | 128448.741% |
| Belite Bio, Inc | -31.52 Million USD | 14861.648% |
| XOMA Corporation | -39.36 Million USD | 11924.094% |
| ARS Pharmaceuticals, Inc. | -67.44 Million USD | 7000.529% |
| Bionomics Limited | -9.83 Million USD | 47413.229% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 5641.704% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | 13549.113% |
| uniQure N.V. | -253.1 Million USD | 1938.878% |
| Cassava Sciences, Inc. | -95.68 Million USD | 4963.984% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 63768.093% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 3693.866% |
| Forte Biosciences, Inc. | -32.47 Million USD | 14430.758% |
| Anebulo Pharmaceuticals, Inc. | -8.05 Million USD | 57912.752% |
| Enlivex Therapeutics Ltd. | -28.21 Million USD | 16593.143% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | 1436581.481% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | 41875.424% |
| FibroBiologics, Inc. Common Stock | -15.9 Million USD | 29369.857% |
| Altimmune, Inc. | -87.93 Million USD | 5392.773% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 5154.573% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | 13549.113% |
| Compugen Ltd. | -12.51 Million USD | 37286.002% |
| Peak Bio, Inc. | -1356.23 USD | 343171980.876% |
| Zevra Therapeutics, Inc. | -48.59 Million USD | 9676.937% |
| Benitec Biopharma Inc. | -22.49 Million USD | 20794.531% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 2020.818% |
| NKGen Biotech, Inc. Common Stock | -28.54 Million USD | 16405.924% |
| Zura Bio Limited | -60.56 Million USD | 7784.89% |
| PolyPid Ltd. | -20.26 Million USD | 23068.958% |
| Aileron Therapeutics, Inc. | -15.61 Million USD | 29909.774% |
| NKGen Biotech, Inc. Warrants | -28.54 Million USD | 16405.924% |
| Instil Bio, Inc. | -146.12 Million USD | 3285.147% |
| argenx SE | -216.02 Million USD | 2254.492% |
| Immunome, Inc. | -28.27 Million USD | 16562.806% |
| Compass Therapeutics, Inc. | -48.47 Million USD | 9701.634% |
| Verona Pharma plc | -52.46 Million USD | 8970.62% |
| enGene Holdings Inc. Warrants | -94.77 Million USD | 5010.944% |
| Shattuck Labs, Inc. | -87.61 Million USD | 5412.104% |
| CervoMed Inc. | -2.17 Million USD | 214394.199% |
| LENZ Therapeutics, Inc. | -122.24 Million USD | 3907.303% |
| Plus Therapeutics, Inc. | -12.69 Million USD | 36767.455% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | 9761.228% |
| Moolec Science SA | -52.07 Million USD | 9037.402% |
| Enveric Biosciences, Inc. | -17.13 Million USD | 27254.051% |
| Inovio Pharmaceuticals, Inc. | -130.39 Million USD | 3669.417% |
| AnaptysBio, Inc. | -143.16 Million USD | 3350.957% |
| Design Therapeutics, Inc. | -66.32 Million USD | 7117.263% |
| Leap Therapeutics, Inc. | -80.98 Million USD | 5846.848% |
| NeurAxis, Inc. | -6.66 Million USD | 69935.749% |
| Seelos Therapeutics, Inc. | -37.75 Million USD | 12429.007% |
| Lumos Pharma, Inc. | -36.57 Million USD | 12826.825% |
| Achilles Therapeutics plc | -70.44 Million USD | 6707.138% |
| enGene Holdings Inc. Common Stock | -94.77 Million USD | 5010.944% |
| 180 Life Sciences Corp. | -22.13 Million USD | 21127.353% |
| Opiant Pharmaceuticals, Inc. | 5.82 Million USD | -79742.216% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | 190735.427% |
| Nutriband Inc. | -5.12 Million USD | 90970.805% |
| ORIC Pharmaceuticals, Inc. | -109.74 Million USD | 4340.806% |
| CG Oncology, Inc. Common stock | -55.43 Million USD | 8496.233% |
| Fractyl Health, Inc. Common Stock | -50.55 Million USD | 9307.122% |
| Rani Therapeutics Holdings, Inc. | -65.27 Million USD | 7229.923% |
| MoonLake Immunotherapeutics | -54.1 Million USD | 8701.377% |
| Palisade Bio, Inc. | -12.28 Million USD | 37997.565% |
| Tourmaline Bio, Inc. | -45.37 Million USD | 10356.964% |
| Beam Therapeutics Inc. | -156.47 Million USD | 3074.443% |
| Neurogene Inc. | -52.28 Million USD | 9001.427% |
| Mirum Pharmaceuticals, Inc. | -136.49 Million USD | 3509.92% |
| AEON Biopharma, Inc. | -48.36 Million USD | 9723.87% |
| CARGO Therapeutics, Inc. Common Stock | -93.01 Million USD | 5103.548% |
| Sesen Bio, Inc. | -50.84 Million USD | 9254.603% |
| Enliven Therapeutics, Inc. | -81.93 Million USD | 5780.564% |
| Kiora Pharmaceuticals, Inc. | -12.35 Million USD | 37785.76% |
| Iovance Biotherapeutics, Inc. | -427.43 Million USD | 1188.875% |
| Taysha Gene Therapies, Inc. | -105.19 Million USD | 4524.271% |
| Athira Pharma, Inc. | -116.7 Million USD | 4088.072% |
| Vaccinex, Inc. | -19.74 Million USD | 23667.956% |
| HCW Biologics Inc. | -23.57 Million USD | 19841.215% |
| XOMA Corporation | -39.36 Million USD | 11924.094% |
| Nektar Therapeutics | -243.1 Million USD | 2014.466% |
| Arvinas, Inc. | -394.8 Million USD | 1278.875% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | -2466276.268% |
| Merus N.V. | -149.2 Million USD | 3219.291% |
| Omega Therapeutics, Inc. | -93.49 Million USD | 5078.286% |
| Quince Therapeutics, Inc. | -31.26 Million USD | 14988.676% |
| Rezolute, Inc. | -68.42 Million USD | 6902.099% |
| Clene Inc. | -43.24 Million USD | 10863.396% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | 30278.593% |
| BeyondSpring Inc. | -21.54 Million USD | 21707.242% |
| Synlogic, Inc. | -55.16 Million USD | 8537.483% |
| Allarity Therapeutics, Inc. | -12.08 Million USD | 38618.58% |
| Phio Pharmaceuticals Corp. | -10.64 Million USD | 43834.26% |
| Peak Bio, Inc. | -1356.23 USD | 343171980.876% |
| Werewolf Therapeutics, Inc. | -32.46 Million USD | 14436.054% |
| Krystal Biotech, Inc. | 17.9 Million USD | -25895.308% |
| Karyopharm Therapeutics Inc. | -118.42 Million USD | 4030.149% |
| SpringWorks Therapeutics, Inc. | -341.34 Million USD | 1463.485% |
| Lipella Pharmaceuticals Inc. | -4.6 Million USD | 101136.985% |
| MannKind Corporation | 15.12 Million USD | -30663.434% |
| Ikena Oncology, Inc. | -74.39 Million USD | 6355.897% |
| Cyclerion Therapeutics, Inc. | -12.59 Million USD | 37058.628% |
| Gyre Therapeutics, Inc. | 20.32 Million USD | -22796.64% |
| Gossamer Bio, Inc. | -172.15 Million USD | 2803.541% |
| CohBar, Inc. | -12.06 Million USD | 38673.62% |
| Cognition Therapeutics, Inc. | -25.5 Million USD | 18345.325% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | 15601.082% |
| Legend Biotech Corporation | -477.87 Million USD | 1073.941% |
| Mural Oncology plc | -192.72 Million USD | 2515.006% |
| Biora Therapeutics, Inc. | -114.05 Million USD | 4180.699% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 28927.019% |
| Disc Medicine, Inc. | -91.02 Million USD | 5213.101% |
| Champions Oncology, Inc. | -5.05 Million USD | 92189.434% |
| REGENXBIO Inc. | -239.46 Million USD | 2043.591% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | 43523.389% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 8447.442% |
| Cellectar Biosciences, Inc. | -38.76 Million USD | 12105.179% |
| Edgewise Therapeutics, Inc. | -112.8 Million USD | 4225.844% |
| Vaxart, Inc. | -74.72 Million USD | 6328.604% |
| PharmaCyte Biotech, Inc. | - USD | -Infinity% |
| Aldeyra Therapeutics, Inc. | -35.2 Million USD | 13319.044% |
| Cellectis S.A. | -98.09 Million USD | 4844.584% |
| Longeveron Inc. | -20.06 Million USD | 23301.396% |
| Repare Therapeutics Inc. | -114.27 Million USD | 4172.878% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 1159.709% |
| Inozyme Pharma, Inc. | -74.81 Million USD | 6321.194% |
| Revolution Medicines, Inc. | -430.58 Million USD | 1180.909% |
| Nymox Pharmaceutical Corporation | -6.28 Million USD | 74105.406% |
| Third Harmonic Bio, Inc. | -30.78 Million USD | 15216.438% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 6339.71% |
| AN2 Therapeutics, Inc. | 4.9 Million USD | -94825.556% |
| Anixa Biosciences, Inc. | -10.96 Million USD | 42545.964% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | -1.064% |
| Denali Therapeutics Inc. | -179.97 Million USD | 2686.055% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | 4888554.752% |
| Veru Inc. | -89.97 Million USD | 5272.737% |
| Corvus Pharmaceuticals, Inc. | -26.87 Million USD | 17416.021% |
| Cingulate Inc. | -22.95 Million USD | 20377.944% |
| Passage Bio, Inc. | -98.34 Million USD | 4832.716% |
| Context Therapeutics Inc. | -25.06 Million USD | 18671.803% |
| Exicure, Inc. | -15.53 Million USD | 30051.734% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 2358.619% |
| Oramed Pharmaceuticals Inc. | -36.97 Million USD | 12687.084% |
| Scinai Immunotherapeutics Ltd. | -5.96 Million USD | 78156.605% |
| Rhythm Pharmaceuticals, Inc. | -168.46 Million USD | 2862.727% |
| Nuvalent, Inc. | -149.49 Million USD | 3213.344% |
| ABVC BioPharma, Inc. | -8.13 Million USD | 57330.232% |
| Carisma Therapeutics, Inc. | -85.89 Million USD | 5518.539% |
| Unicycive Therapeutics, Inc. | -30.17 Million USD | 15522.493% |
| OmniAb, Inc. | -49.73 Million USD | 9458.75% |
| Anew Medical, Inc. | -1.3 Million USD | 357884.201% |
| Fennec Pharmaceuticals Inc. | -12.36 Million USD | 37743.158% |
| Lipocine Inc. | -16.32 Million USD | 28613.724% |
| Lexeo Therapeutics, Inc. Common Stock | -66.67 Million USD | 7080.951% |
| Nautilus Biotechnology, Inc. | -74.3 Million USD | 6363.812% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | 12305.107% |
| G1 Therapeutics, Inc. | -39.01 Million USD | 12029.564% |
| Bellerophon Therapeutics, Inc. | -22.18 Million USD | 21080.931% |
| Sage Therapeutics, Inc. | -545.07 Million USD | 953.872% |
| Ocugen, Inc. | -64.82 Million USD | 7279.416% |
| Mind Medicine (MindMed) Inc. | -92.57 Million USD | 5127.763% |
| Q32 Bio Inc. | -86.5 Million USD | 5480.454% |
| Brainstorm Cell Therapeutics Inc. | -16.92 Million USD | 27595.717% |
| Alumis Inc. Common Stock | -156.89 Million USD | 3066.537% |
| Equillium, Inc. | -12.13 Million USD | 38444.043% |
| Kyverna Therapeutics, Inc. | -58.47 Million USD | 8059.707% |
| Coya Therapeutics, Inc. | -7.9 Million USD | 58988.96% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | 24776.35% |
| Galera Therapeutics, Inc. | -46.69 Million USD | 10067.875% |
| Evelo Biosciences, Inc. | -106.34 Million USD | 4476.51% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | 26120.611% |
| Dominari Holdings Inc. | -22.44 Million USD | 20840.642% |
| Edesa Biotech, Inc. | -8.19 Million USD | 56926.854% |
| vTv Therapeutics Inc. | -25.41 Million USD | 18414.969% |
| Bio-Techne Corporation | 326.66 Million USD | -1324.771% |
| Agios Pharmaceuticals, Inc. | -384.86 Million USD | 1309.31% |
| Harmony Biosciences Holdings, Inc. | 216.38 Million USD | -2050.849% |
| Prelude Therapeutics Incorporated | -131.1 Million USD | 3649.898% |
| Candel Therapeutics, Inc. | -37.43 Million USD | 12534.079% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 3180.191% |
| Nkarta, Inc. | -120.48 Million USD | 3963.016% |
| BioCardia, Inc. | -11.56 Million USD | 40361.246% |
| Iterum Therapeutics plc | -34.58 Million USD | 13559.225% |